Abstract
Scorpion envenomation is a serious health problem in tropical and subtropical zones. The access to scorpion antivenom is sometimes limited in availability and specificity. The classical production process is cumbersome, from the hyper-immunization of the horses to the IgG digestion and purification of the F(ab)′2 antibody fragments. The production of recombinant antibody fragments in Escherichia coli is a popular trend due to the ability of this microbial host to produce correctly folded proteins. Small recombinant antibody fragments, such as single-chain variable fragments (scFv) and nanobodies (VHH), have been constructed to recognize and neutralize the neurotoxins responsible for the envenomation symptoms in humans. They are the focus of interest of the most recent studies and are proposed as potentially new generation of pharmaceuticals for their use in immunotherapy against scorpion stings of the Buthidae family. This literature review comprises the current status on the scorpion antivenom market and the analyses of cross-reactivity of commercial scorpion anti-serum against non-specific scorpion venoms. Recent studies on the production of new recombinant scFv and nanobodies will be presented, with a focus on the Androctonus and Centruroides scorpion species. Protein engineering-based technology could be the key to obtaining the next generation of therapeutics capable of neutralizing and cross-reacting against several types of scorpion venoms.
Key points
• Commercial antivenoms consist of predominantly purified equine F(ab)′2fragments.
• Nanobody-based antivenom can neutralize Androctonus venoms and have a low immunogenicity.
• Affinity maturation and directed evolution are used to obtain potent scFv families against Centruroides scorpions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All data generated or analyzed during this study is included in this published article.
References
Abderrazek RB, Hmila I, Vincke C, Benlasfar Z, Pellis M, Dabbek H, Saerens D, El Ayeb M, Muyldermans S, Bouhaouala-Zahar B (2009) Identification of potent nanobodies to neutralize the most poisonous polypeptide from scorpion venom. Biochem J 424:263–272. https://doi.org/10.1042/BJ20090697
Abroug F, ElAtrous S, Nouria S, Haguiga H, Touzi N, Bouchoucha S (1999) Serotherapy in scorpion envenomation: a randomised controlled trial. Lancet 354:906–909. https://doi.org/10.1016/S0140-6736(98)12083-4
Alirahimi E, Kazemi-Lomedasht F, Shahbazzadeh D, Habibi-Anbouhi M, Hosseininejad Chafi M, Sotoudeh N, Ghaderi H, Muyldermans S, Behdani M (2018) Nanobodies as novel therapeutic agents in envenomation. Biochim Biophys Acta - Gen Subj 1862:2955–2965. https://doi.org/10.1016/j.bbagen.2018.08.019
Alonso Villela SM, Ghezal-Kraïem H, Bouhaouala-Zahar B, Bideaux C, Aceves Lara CA, Fillaudeau L (2021) Effect of temperature on the production of a recombinant antivenom in fed-batch mode. Appl Microbiol Biotechnol 105:1017–1030. https://doi.org/10.1007/s00253-021-11093-5
Alvarenga L, Zahid M, Tommaso A, Juste M, Aubrey N, Billiald P, Muzard J (2014) Engineering venom’s toxin-neutralizing antibody fragments and its therapeutic potential. Toxins (Basel) 6:2541–2567. https://doi.org/10.3390/toxins6082541
Amaro I, Riaño-Umbarila L, Becerril B, Possani LD (2011) Isolation and characterization of a human antibody fragment specific for Ts1 toxin from Tityus serrulatus scorpion. Immunol Lett 139:73–79. https://doi.org/10.1016/j.imlet.2011.05.002
Ariff AB, Nelofer R, Rahman RNZRA, Basri M (2015) Kinetics and modelling of batch fermentation for the production of organic solvent tolerant and thermostable lipase by recombinant E. coli. Turkish J Biochem 40:298–309. https://doi.org/10.1515/tjb-2015-0017
Asaadi Y, Jouneghani FF, Janani S, Rahbarizadeh F (2021) A comprehensive comparison between camelid nanobodies and single chain variable fragments. Biomark Res 9:87. https://doi.org/10.1186/s40364-021-00332-6
Aubrey N, Devaux C, Sizaret PY, Rochat H, Goyffon M, Billiald P (2003) Design and evaluation of a diabody to improve protection against a potent scorpion neurotoxin. Cell Mol Life Sci 60:617–628. https://doi.org/10.1007/s000180300053
Aubrey N, Muzard J, Christophe J, Goyffon M, Devaux C, Billiald P (2004) Engineering of a recombinant Fab from a neutralizing IgG directed against scorpion neurotoxin AahI, and functional evaluation versus other antibody fragments. Toxicon 43:233–241. https://doi.org/10.1016/j.toxicon.2003.11.024
Aubrey N, Devaux C, Goyffon M, Rochat H, Billiald P (2001) A recombinant scFv/streptavidin-binding peptide fusion protein for the quantitative determination of the scorpion venom neurotoxin AahI.https://doi.org/10.1515/BC.2001.197
Ayyar BV, Arora S, Ravi SS (2017) Optimizing antibody expression: the nuts and bolts. Methods 116:51–62. https://doi.org/10.1016/j.ymeth.2017.01.009
Babaeipour V, Shojaosadati SA, Khalilzadeh R, Maghsoudi N, Farnoud AM (2010) Enhancement of human γ-Interferon production in recombinant E. coli using batch cultivation. Appl Biochem Biotechnol 160:2366–2376. https://doi.org/10.1007/s12010-009-8718-5
Baeshen MN, Al-He** AM, Bora RS, Ahmed MMM, Ramadan HAI, Saini KS, Baeshen NA, Redwan EM (2015) Production of biopharmaceuticals in E. coli: current scenario and future perspectives. J Microbiol Biotechnol 25:953–962. https://doi.org/10.4014/jmb.1412.12079
Banerjee S, Curto EV, Beckman M, Brown GB, Zhong J, Krishna NR (2006) Expression of functional scorpion neurotoxin Lqq-V in E.coli. Peptides 27:49–54. https://doi.org/10.1016/j.peptides.2005.06.023
Baneyx F, Mujacic M (2004) Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol 22:1399–1408. https://doi.org/10.1038/nbt1029
Barona J, Otero R, Núñez V (2004) Aspectos toxinológicos e inmunoquímicos del veneno del escorpión Tityus pachyurus Pocock de Colombia: capacidad neutralizante de antivenenos producidos en Latinoamérica. Biomedica 24:42. https://doi.org/10.7705/biomedica.v24i1.1247
Bawaskar HS, Bawaskar PH (1991) Scorpion sting: a review of 121 cases. J Wilderness Med 2:164–174. https://doi.org/10.1580/0953-9859-2.3.164
Ben Abderrazek R, Vincke C, Hmila I, Saerens D, Abidi N, El Ayeb M, Muyldermans S, Bouhaouala-Zahar B (2011) Development of Cys38 knock-out and humanized version of NbAahII10 nanobody with improved neutralization of AahII Scorpion toxin. Protein Eng Des Sel 24:727–735. https://doi.org/10.1093/protein/gzr037
Ben Abderrazek R, Ksouri A, Idoudi F, Dhaouadi S, Hamdi E, Vincke C, Farah A, Benlasfar Z, Majdoub H, El Ayeb M, Muyldermans S, Bouhaouala-Zahar B (2022) Neutralizing dromedary-derived nanobodies against BotI-like toxin from the most hazardous scorpion venom in the Middle East and North Africa Region. Front Immunol 13:1–13. https://doi.org/10.3389/fimmu.2022.863012
Billiald P, Motta G, Vaux DJ (1995) Production of a functional anti-scorpion hemocyanin scFv in Escherichia coli. Arch Biochem Biophys 317:429–438. https://doi.org/10.1006/abbi.1995.1185
Blight MA, Chervaux C, Holland IB (1994) Protein secretion pathway in Escherichia coli. Curr Opin Biotechnol 5:468–474. https://doi.org/10.1146/annurev.mi.39.100185.003151
Boldrini-França J, Rodrigues RS, Santos-Silva LK, de Souza DLN, Gomes MSR, Cologna CT, de Pauw E, Quinton L, Henrique-Silva F, de Melo RV, Arantes EC (2015) Expression of a new serine protease from Crotalus durissus collilineatus venom in Pichia pastoris and functional comparison with the native enzyme. Appl Microbiol Biotechnol 99:9971–9986. https://doi.org/10.1007/s00253-015-6836-2
Borges A, Lomonte B, Angulo Y, Acosta de Patiño H, Pascale JM, Otero R, Miranda RJ, De Sousa L, Graham MR, Gómez A, Pardal PPO, Ishikawa E, Bonilla F, Castillo A, de Avila RAM, Gómez JP, Caro-López JA (2020) Venom diversity in the Neotropical scorpion genus Tityus: Implications for antivenom design emerging from molecular and immunochemical analyses across endemic areas of scorpionism. Acta Trop 204:105346. https://doi.org/10.1016/j.actatropica.2020.105346
Bouhaouala-Zahar B, Ducancel F, Zenouaki I, Khalifa R, Borchani L, Pelhate M, Boulain J-C, Ayeb M, Menez A, Karoui H (1996) A recombinant insect-specific alpha-toxin of Buthus occitanus tunetanus scorpion confers protection against homologous mammal toxins. Eur J Biochem 238:653–660. https://doi.org/10.1111/j.1432-1033.1996.0653w.x
Bouhaouala-Zahar B, Ben Abderrazek R, Hmila I, Abidi N, Muyldermans S, El Ayeb M (2011) Immunological aspects of scorpion toxins: current status and perspectives. Inflamm Allergy Drug Targets 10:358–368. https://doi.org/10.2174/187152811797200713
Calleja D, Kavanagh J, de Mas C, López-Santín J (2016) Simulation and prediction of protein production in fed-batch E. coli cultures: an engineering approach. Biotechnol Bioeng 113:772–782. https://doi.org/10.1002/bit.25842
Candido DM, Lucas S (2004) Maintenance of scorpions of the genus Tityus Koch (Scorpiones, Buthidae) for venom obtention at Instituto Butantan, São Paulo, Brazil. J Venom Anim Toxins Incl Trop Dis 10:86–97. https://doi.org/10.1590/S1678-91992004000100007
Cantu-Bustos JE, Vargas-Cortez T, Morones-Ramirez JR, Balderas-Renteria I, Galbraith DW, McEvoy MM, Zarate X (2016) Expression and purification of recombinant proteins in Escherichia coli tagged with the metal-binding protein CusF. Protein Expr Purif 121:61–65. https://doi.org/10.1016/j.pep.2016.01.007
Cao P, Yu J, Lu W, Cai X, Wang Z, Gu Z, Zhang J, Ye T, Wang M (2010) Expression and purification of an antitumor-analgesic peptide from the venom of Mesobuthus martensii Karsch by small ubiquitin-related modifier fusion in Escherichia coli. Biotechnol Prog 26:1240–1244. https://doi.org/10.1002/btpr.433
Carmo AO, Chatzaki M, Horta CCR, Magalhães BF, Oliveira-Mendes BBR, Chávez-Olórtegui C, Kalapothakis E (2015) Evolution of alternative methodologies of scorpion antivenoms production. Toxicon 97:64–74. https://doi.org/10.1016/j.toxicon.2015.02.007
Carvalho RJ, Cabrera-Crespo J, Tanizaki MM, Gonçalves VM (2012) Development of production and purification processes of recombinant fragment of pneumococcal surface protein A in Escherichia coli using different carbon sources and chromatography sequences. Appl Microbiol Biotechnol 94:683–694. https://doi.org/10.1007/s00253-011-3649-9
Chgoury F, Benabderrazek R, Tounsi H, Oukkach N, Hmila I, Boubaker S, Ayeb M, Saïle R, N G, Bouhaouala-Zahar B (2015) Effectiveness of the Androctonus Australis Hector nanobody Nbf12-10 antivenom to neutralize significantly the toxic effect and tissue damage provoked by fraction of Androctonus mauretanicus (Morocco) scorpion venom. Biochem Pharmacol (Los Angel) 4:174. https://doi.org/10.4172/2167-0501.1000174
Chippaux J-P (2012) Emerging options for the management of scorpion stings. Drug Des Devel Ther 6:165. https://doi.org/10.2147/DDDT.S24754
Chippaux J-P, Goyffon M (1998) Venoms, antivenoms and immunotherapy. Toxicon 36:823–846. https://doi.org/10.1016/S0041-0101(97)00160-8
Chippaux J-P, Goyffon M (2008) Epidemiology of scorpionism: a global appraisal. Acta Trop 107:71–79. https://doi.org/10.1016/j.actatropica.2008.05.021
Cockshott A, Bogle I (1999) Modelling the effects of glucose feeding on a recombinant E-coli fermentation. Bioprocess Eng 20:83–90. https://doi.org/10.1007/PL00009037
Conrath KE, Lauwereys M, Galleni M, Matagne A, Frère J-M, Kinne J, Wyns L, Muyldermans S (2001) β-lactamase inhibitors derived from single-domain antibody fragments elicited in the Camelidae. Antimicrob Agents Chemother 45:2807–2812. https://doi.org/10.1128/AAC.45.10.2807-2812.2001
D’Suze G, Moncada S, González C, Sevcik C, Alagón A (2007) Antigenic cross-reactivity between sixteen venoms from scorpions belonging to six genera. Clin Toxicol 45:158–163. https://doi.org/10.1080/15563650601005787
D’Suze G, Castillo C, Sevcik C, Brazón J, Malave C, Hernandez D, Zerpa N (2013) Scorpionism and dangerous species of Venezuela. In: Gopalakrishnakone P (eds) Toxinology. Springer, Dordrecht, pp 1–23. https://doi.org/10.1007/978-94-007-6647-1_24-1
Darvish M, Behdani M, Shokrgozar MA, Pooshang-Bagheri K, Shahbazzadeh D (2015) Development of protective agent against Hottentotta saulcyi venom using camelid single-domain antibody. Mol Immunol 68:412–420. https://doi.org/10.1016/j.molimm.2015.10.002
Das B, Patra A, Puzari U, Deb P, Mukherjee AK (2022) In vitro laboratory analyses of commercial anti-scorpion (Mesobuthus tamulus) antivenoms reveal their quality and safety but the prevalence of a low proportion of venom-specific antibodies. Toxicon 215:37–48. https://doi.org/10.1016/j.toxicon.2022.06.001
de Marco A (2009) Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microb Cell Fact 8:26. https://doi.org/10.1186/1475-2859-8-26
de Marco A (2015) Recombinant antibody production evolves into multiple options aimed at yielding reagents suitable for application-specific needs. Microb Cell Fact 14:125. https://doi.org/10.1186/s12934-015-0320-7
Deffar K, Shi H, Li L, Wang X, Zhu X (2009) Nanobodies - the new concept in antibody engineering. African J Biotechnol 8:2645–2652
Dehesa-Dávila M, Possani LD (1994) Scorpionism and serotherapy in Mexico. Toxicon 32:1015–1018. https://doi.org/10.1016/0041-0101(94)90383-2
Dehghani R, Arani MG (2015) Scorpion sting prevention and treatment in ancient Iran. J Tradit Complement Med 5:75–80. https://doi.org/10.1016/j.jtcme.2014.11.007
DeLisa MP, Li J, Rao G, Weigand W, a, Bentley WE, (1999) Monitoring GFP-operon fusion protein expression during high cell density cultivation of Escherichia coli using an on-line optical sensor. Biotechnol Bioeng 65:54–64. https://doi.org/10.1002/(SICI)1097-0290(19991005)65:1%3c54::AID-BIT7%3e3.0.CO;2-R
Devaux C, Moreau E, Goyffon M, Rochat H, Billiald P (2001) Construction and functional evaluation of a single-chain antibody fragment that neutralizes toxin Aahl from the venom of the scorpion Androctonus australis hector. Eur J Biochem 268:694–702. https://doi.org/10.1046/j.1432-1327.2001.01923.x
Donovan RS, Robinson CW, Glick BR (1996) Review: optimizing inducer and culture conditions for expression of foreign proteins under the control of the lac promoter. J Ind Microbiol 16:145–154. https://doi.org/10.1007/BF01569997
Dudler T, Chen WQ, Wang S, Schneider T, Annand RR, Dempcy RO, Crameri R, Gmachl M, Suter M, Gelb MH (1992) High-level expression in Escherichia coli and rapid purification of enzymatically active honey bee venom phospholipase A2. Biochim Biophys Acta 1165:201–210. https://doi.org/10.1016/0005-2760(92)90188-2
El Hafny B, Ghalim N (2002) Scorpion envenomations and antivenom therapy in Morocco. Bull La Société Pathol Exot 95:200–204
El Ayeb M, Bahraoui EM, Granier C, Rochat H (1986) Use of antibodies specific to defined regions of scorpion.alpha.-toxin to study its interaction with its receptor site on the sodium channel. Biochemistry 25:6671–6678. https://doi.org/10.1021/bi00369a052
Fernández-Taboada G, Riaño-Umbarila L, Olvera-Rodríguez A, Gómez-Ramírez IV, Losoya-Uribe LF, Becerril B (2021) The venom of the scorpion Centruroides limpidus, which causes the highest number of stings in Mexico, is neutralized by two recombinant antibody fragments. Mol Immunol 137:247–255. https://doi.org/10.1016/j.molimm.2021.07.010
Frenzel A, Hust M, Schirrmann T (2013) Expression of recombinant antibodies. Front Immunol 4:1–20. https://doi.org/10.3389/fimmu.2013.00217
Gao J, Wang Y, Liu Z, Wang Z (2010) Phage display and its application in vaccine design. Ann Microbiol 60:13–19. https://doi.org/10.1007/s13213-009-0014-7
Garcia-Ochoa F, Gomez E (2009) Bioreactor scale-up and oxygen transfer rate in microbial processes: an overview. Biotechnol Adv 27:153–176. https://doi.org/10.1016/j.biotechadv.2008.10.006
Garcia-Ochoa F, Gomez E, Santos VE, Merchuk JC (2010) Oxygen uptake rate in microbial processes: an overview. Biochem Eng J 49:289–307. https://doi.org/10.1016/j.bej.2010.01.011
Ghalim N, El-Hafny B, Sebti F, Heikel J, Lazar N, Moustanir R, Benslimane A (2000) Scorpion envenomation and serotherapy in Morocco. Am J Trop Med Hyg 62:277–283. https://doi.org/10.4269/ajtmh.2000.62.277
Graumann K, Premstaller A (2006) Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol J 1:164–186. https://doi.org/10.1002/biot.200500051
Gupta SK, Shukla P (2017a) Microbial platform technology for recombinant antibody fragment production: a review. Crit Rev Microbiol 43:31–42. https://doi.org/10.3109/1040841X.2016.1150959
Gupta SK, Shukla P (2017b) Sophisticated cloning, fermentation, and purification technologies for an enhanced therapeutic protein production: a review. Front Pharmacol 8:1–17. https://doi.org/10.3389/fphar.2017.00419
Hamilton S, Odili J, Pacifico MD, Wilson GD, Kupsch JM (2003) Effect of imidazole on the solubility of a his-tagged antibody fragment. Hybrid Hybridomics 22:347–355. https://doi.org/10.1089/153685903771797048
Hammoudi-Triki D, Laraba-Djebari F (2003) Application of ELISA for the quantification of Androctonus australis hector venom in the envenomed serum of people and rats before and after immunotherapy. Bull Soc Pathol Exot 96:297–301
Han T, Ming H, Deng L, Zhu H, Liu Z, Zhang J, Song Y (2017) A novel expression vector for the improved solubility of recombinant scorpion venom in Escherichia coli. Biochem Biophys Res Commun 482:120–125. https://doi.org/10.1016/j.bbrc.2016.09.047
Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C, Muyldermans S (2013) Nanobodies and their potential applications. Nanomedicine 8:1013–1026. https://doi.org/10.2217/nnm.13.86
Hellal H, Guerinik M, Griene L, Laid Y, Mesbah S, Merad R, Alamir B (2012) Données épidémiologiques sur l’envenimation scorpionique en Algérie. Bull Soc Pathol Exot 105:189–193. https://doi.org/10.1007/s13149-012-0234-4
Helma J, Cardoso MC, Muyldermans S, Leonhardt H (2015) Nanobodies and recombinant binders in cell biology. J Cell Biol 209:633–644. https://doi.org/10.1083/jcb.201409074
Hmaidi R, Ksouri A, Benabderrazek R, Antonietti V, Sonnet P, Gautier M, Bouhaouala-Zahar B, Ouadid-Ahidouch H (2022) The pharmacological and structural basis of the AahII–NaV1.5 interaction and modulation by the anti-AahII Nb10 nanobody. Front Pharmacol 13:1–11. https://doi.org/10.3389/fphar.2022.821181
Hmila I, Abdallah RBA-B, Saerens D, Benlasfar Z, Conrath K, El AM, Muyldermans S, Bouhaouala-Zahar B (2008) VHH, bivalent domains and chimeric heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI’. Mol Immunol 45:3847–3856. https://doi.org/10.1016/j.molimm.2008.04.011
Hmila I, Saerens D, Ben Abderrazek R, Vincke C, Abidi N, Benlasfar Z, Govaert J, El Ayeb M, Bouhaouala-Zahar B, Muyldermans S (2010) A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J 24:3479–3489. https://doi.org/10.1096/fj.09-148213
Hmila I, Cosyns B, Tounsi H, Roosens B, Caveliers V, Ben AR, Boubaker S, Muyldermans S, El Ayeb M, Bouhaouala-Zahar B, Lahoutte T (2012) Pre-clinical studies of toxin-specific nanobodies: evidence of in vivo efficacy to prevent fatal disturbances provoked by scorpion envenoming. Toxicol Appl Pharmacol 264:222–231. https://doi.org/10.1016/j.taap.2012.07.033
Hoffman BJ, Broadwater JA, Johnson P, Harper J, Fox BG, Kenealy WR (1995) Lactose fed-batch overexpression of recombinant metalloproteins in Escherichia coli BL21(DE3): Process control yielding high levels of metal-incorporated, soluble protein. Protein Expr Purif 6:646–654
Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, Winter G (1991) Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 19:4133–4137. https://doi.org/10.1093/nar/19.15.4133
Horta ACL, Sargo CR, Da Silva AJ, De Carvalho GM, Dos Santos MP, Gonçalves VM, Zangirolami TC, De Campos GR (2012) Intensification of high cell-density cultivations of rE. coli for production of S. pneumoniae antigenic surface protein, PspA3, using model-based adaptive control. Bioprocess Biosyst Eng 35:1269–1280. https://doi.org/10.1007/s00449-012-0714-4
Horta ACL, Da Silva AJ, Sargo CR, Cavalcanti-Montaño ID, Galeano-Suarez ID, Velez AM, Santos MP, Gonçalves VM, Giordano RC, Zangirolami TC (2015) On-line monitoring of biomass concentration based on a capacitance sensor: assessing the methodology for different bacteria and yeast high cell density fed-batch cultures. Braz J Chem Eng 32:821–829. https://doi.org/10.1590/0104-6632.20150324s00003534
Hua X, Fan D, Luo Y, Zhang X, Shi H, Mi Y, Ma X, Shang L, Zhao G (2006) Kinetics of high cell density fed-batch culture of recombinant Escherichia coli producing human-like collagen. Chin J Chem Eng 14:242–247. https://doi.org/10.1016/S1004-9541(06)60065-7
Huang C-J, Lin H, Yang X (2012) Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. J Ind Microbiol Biotechnol 39:383–399. https://doi.org/10.1007/s10295-011-1082-9
Ismail M (1995) The scorpion envenoming syndrome. Toxicon 33:825–858. https://doi.org/10.1016/0041-0101(95)00005-7
Jank L, Pinto-Espinoza C, Duan Y, Koch-Nolte F, Magnus T, Rissiek B (2019) Current approaches and future perspectives for nanobodies in stroke diagnostic and therapy. Antibodies 8:5. https://doi.org/10.3390/antib8010005
Jaroszewicz W, Morcinek-Orłowska J, Pierzynowska K, Gaffke L, Węgrzyn G (2022) Phage display and other peptide display technologies. FEMS Microbiol Rev 46:1–25. https://doi.org/10.1093/femsre/fuab052
Jenzsch M, Simutis R, Luebbert A (2006) Generic model control of the specific growth rate in recombinant Escherichia coli cultivations. J Biotechnol 122:483–493. https://doi.org/10.1016/j.jbiotec.2005.09.013
Johnson TM, Quick MW, Sakai TT, Krishna NR (2000) Expression of functional recombinant scorpion beta-neurotoxin Css II in E. coli. Peptides 21:767–772. https://doi.org/10.1016/S0196-9781(00)00206-0
Juárez-González VR, Riaño-Umbarila L, Quintero-Hernández V, Olamendi-Portugal T, Ortiz-León M, Ortíz E, Possani LD, Becerril B (2005) Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2. J Mol Biol 346:1287–1297. https://doi.org/10.1016/j.jmb.2004.12.060
Juste M, Martin-Eauclaire MF, Devaux C, Billiald P, Aubrey N (2007) Using a recombinant bispecific antibody to block Na+-channel toxins protects against experimental scorpion envenoming. Cell Mol Life Sci 64:206–218. https://doi.org/10.1007/s00018-006-6401-3
Kangwa M, Yelemane V, Polat AN, Gorrepati KDD, Grasselli M, Fernández-Lahore M (2015) High-level fed-batch fermentative expression of an engineered Staphylococcal protein A based ligand in E. coli: purification and characterization. AMB Express 5:70. https://doi.org/10.1186/s13568-015-0155-y
Khasa YP, Khushoo A, Mukherjee KJ (2013) Enhancing toxic protein expression in Escherichia coli fed-batch culture using kinetic parameters: human granulocyte-macrophage colony-stimulating factor as a model system. J Biosci Bioeng 115:291–297. https://doi.org/10.1016/j.jbiosc.2012.09.015
Kilikian BV, Suárez ID, Liria CW, Gombert AK (2000) Process strategies to improve heterologous protein production in Escherichia coli under lactose or IPTG induction. Process Biochem 35:1019–1025. https://doi.org/10.1016/S0032-9592(00)00137-0
Kim C-K, Choi J-H, Lee S-B, Lee S-M, Oh J-W (2014) Expression and purification of recombinant human granulocyte colony-stimulating factor in fed-batch culture of Escherichia coli. Appl Biochem Biotechnol 172:2425–2435. https://doi.org/10.1007/s12010-013-0708-y
Kischnick S, Weber B, Verdino P, Keller W, Sanders EA, Anspach FB, Fiebig H, Cromwell O, Suck R (2006) Bacterial fermentation of recombinant major wasp allergen Antigen 5 using oxygen limiting growth conditions improves yield and quality of inclusion bodies. Protein Expr Purif 47:621–628. https://doi.org/10.1016/j.pep.2006.01.009
Korte G, Rinas U, Kracke-Helm H-A, Schügerl K (1991) Structured model for cell growth and enzyme production by recombinant Escherichia coli. Appl Microbiol Biotechnol 35:185–188. https://doi.org/10.1007/BF00184684
Kraïem H, Manon Y, Hmila I, Ben Abderrazek R, Alonso Villela SM, Luc F, Bouhaouala-Zahar B (2019) Expression of the recombinant NbF12–10 and its chimeric antibody format in Escherichia Coli : investigation of fed-batch bioprocess on minimal media. In: Second Mediterranean Congress on Biotechnology. Hammamet, Tunisia
Kuhlmann M, Covic A (2006) The protein science of biosimilars. Nephrol Dial Transplant 21:v4–v8. https://doi.org/10.1093/ndt/gfl474
Kuhn P, Fühner V, Unkauf T, Moreira GMSG, Frenzel A, Miethe S, Hust M (2016) Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display. Proteomics - Clin Appl 10:922–948. https://doi.org/10.1002/prca.201600002
Laïd Y, Oudjehane R, Bachiri K (2012) Envenimation scorpionique: Rapport Annuel sur la situation epidemiologique en Algérie. Institut National de Santé Publique. https://insp.dz/images/PDF/Envenimation%20scorpionique/rapport_scorpion_2009.pdf. Accessed 29 Apr 2023
Laustsen A, Solà M, Jappe E, Oscoz S, Lauridsen L, Engmark M (2016) Biotechnological Trends in Spider and Scorpion Antivenom Development. Toxins (Basel) 8:226. https://doi.org/10.3390/toxins8080226
Le Z, Li X, Yuan P, Liu P, Huang C (2015) Orthogonal optimization of prokaryotic expression of a natural snake venom phospholipase A2 inhibitor from Sinonatrix annularis. Toxicon 108:264–271. https://doi.org/10.1016/j.toxicon.2015.10.018
Ledsgaard L, Kilstrup M, Karatt-Vellatt A, McCafferty J, Laustsen A (2018) Basics of antibody phage display technology. Toxins (basel) 10:236. https://doi.org/10.3390/toxins10060236
Lee K-M, Rhee C-H, Kang C-K, Kim J-H (2006) Statistical medium formulation and process modeling by mixture design of experiment for peptide overexpression in recombinant Escherichia coli. Appl Biochem Biotechnol 135:81–110
Legros C, Feyfant E, Sampieri F, Rochat H, Bougis PE, Martin-Eauclaire MF (1997) Influence of a NH2-terminal extension on the activity of KTX2, a K+ channel blocker purified from Androctonus australis scorpion venom. FEBS Lett 417:123–129. https://doi.org/10.1016/S0014-5793(97)01177-0
Legros C, Kaabi H, El Ayeb M, Céard B, Vacher H, Bougis PE, Martin-Eauclaire M-F (2001) Use of fusion protein constructs to generate potent immunotherapy and protection against scorpion toxins. Vaccine 20:934–942. https://doi.org/10.1016/S0264-410X(01)00379-6
Leong SSJ, Chen WN (2008) Preparing recombinant single chain antibodies. Chem Eng Sci 63:1401–1414. https://doi.org/10.1016/j.ces.2007.11.022
Mansour N (2001) Delai et caracteristiques de la prise en charge des piqués par scorpion dans la region de Sidi-Bouzid. Arch Inst Pasteur Tunis 78:25–31
Marichal-Gallardo PA, Álvarez MM (2012) State-of-the-art in downstream processing of monoclonal antibodies: process trends in design and validation. Biotechnol Prog 28:899–916. https://doi.org/10.1002/btpr.1567
Meddeb-Mouelhi F, Bouhaouala-Zahar B, Benlasfar Z, Hammadi M, Mejri T, Moslah M, Karoui H, Khorchani T, El AM (2003) Immunized camel sera and derived immunoglobulin subclasses neutralizing Androctonus australis hector scorpion toxins. Toxicon 42:785–791. https://doi.org/10.1016/j.toxicon.2003.10.021
Mergulhão FJM, Summers DK, Monteiro GA (2005) Recombinant protein secretion in Escherichia coli. Biotechnol Adv 23:177–202. https://doi.org/10.1016/j.biotechadv.2004.11.003
Morgon AM, Belisario-Ferrari MR, Trevisan-Silva D, Meissner GO, Vuitika L, Marin B, Tashima AK, Gremski LH, Gremski W, Senff-Ribeiro A, Veiga SS, Chaim OM (2016) Expression and immunological cross-reactivity of LALP3, a novel astacin-like metalloprotease from brown spider (Loxosceles intermedia) venom. Biochimie 128–129:8–19. https://doi.org/10.1016/j.biochi.2016.06.003
Mousli M, Goyffon M, Billiald P (1998) Production and characterization of a bivalent single chain Fv/alkaline phosphatase conjugate specific for the hemocyanin of the scorpion Androctonus australis. Biochim Biophys Acta - Gen Subj 1425:348–360. https://doi.org/10.1016/S0304-4165(98)00090-7
Mousli M, Devaux C, Rochat H, Goyffon M, Billiald P (1999) A recombinant single-chain antibody fragment that neutralizes toxin II from the venom of the scorpion Androctonus australis hector. FEBS Lett 442:183–188. https://doi.org/10.1016/S0014-5793(98)01647-0
Muyldermans S (2013) Nanobodies: natural single-domain antibodies. Annu Rev Biochem 82:775–797. https://doi.org/10.1146/annurev-biochem-063011-092449
Nadri M, Trezzani I, Hammouri H, Dhurjati P, Longin R, Lieto J (2006) Modeling and observer design for recombinant Escherichia coli strain. Bioprocess Biosyst Eng 28:217–225. https://doi.org/10.1007/s00449-005-0008-1
Nancib N, Mosrati R, Boudrant J (1993) Modelling of batch fermentation of a recombinant Escherichia coli producing glyceraldehyde-3-phosphate dehydrogenase on a complex selective medium. Chem Eng J 52:B35–B48. https://doi.org/10.1016/0300-9467(93)80056-T
Nuebling CM, Williams DJ (2016) Guidelines for the production, control and regulation of snake antivenom immunoglobulins. World Health Organization. https://www.who.int/publications/m/item/snake-antivenom-immunoglobulins-annex-5-trs-no-1004. Accessed 29 Apr 2023
O’Reilly AO, Cole AR, Lopes JLS, Lampert A, Wallace BA (2014) Chaperone-mediated native folding of a β-scorpion toxin in the periplasm of Escherichia coli. Biochim Biophys Acta - Gen Subj 1840:10–15. https://doi.org/10.1016/j.bbagen.2013.08.021
Overton TW (2014) Recombinant protein production in bacterial hosts. Drug Discov Today 19:590–601. https://doi.org/10.1016/j.drudis.2013.11.008
Ozkan O, Adigüzel S, Ates C, Bozyigit I, Filazi A (2006) Optimization of antiscorpion venom production. J Venom Anim Toxins Incl Trop Dis 12:390–399. https://doi.org/10.1590/S1678-91992006000300004
Palaiomylitou MA, Matis KA, Zouboulis AI, Kyriakidis DA (2002) A kinetic model describing cell growth and production of highly active, recombinant ice nucleation protein in Escherichia coli. Biotechnol Bioeng 78:321–332. https://doi.org/10.1002/bit.10107
Pardon E, Laeremans T, Triest S, Rasmussen SGF, Wohlkönig A, Ruf A, Muyldermans S, Hol WGJ, Kobilka BK, Steyaert J (2014) A general protocol for the generation of Nanobodies for structural biology. Nat Protoc 9:674–693. https://doi.org/10.1038/nprot.2014.039
Pipelzadeh MH, Jalali A, Taraz M, Pourabbas R, Zaremirakabadi A (2007) An epidemiological and a clinical study on scorpionism by the Iranian scorpion Hemiscorpius lepturus. Toxicon 50:984–992. https://doi.org/10.1016/j.toxicon.2007.07.018
Pucca MB, Oliveira FN, Schwartz EF, Arantes EC, Lira-da-Silva RM (2015) Scorpionism and Dangerous Species of Brazil. In: Scorpion Venoms, Toxinology. Springer Netherlands, Dordrecht, pp 299–324
Qi H, Lu H, Qiu H-J, Petrenko V, Liu A (2012) Phagemid vectors for phage display: properties, characteristics and construction. J Mol Biol 417:129–143. https://doi.org/10.1016/j.jmb.2012.01.038
Queiroz AM, Sampaio VS, Mendonça I, Fé NF, Sachett J, Ferreira LCL, Feitosa E, Wen FH, Lacerda M, Monteiro W (2015) Severity of Scorpion Stings in the Western Brazilian Amazon: A Case-Control Study. PLoS One 10:e0128819. https://doi.org/10.1371/journal.pone.0128819
Quintero-Hernández V, Juárez-González VR, Ortíz-León M, Sánchez R, Possani LD, Becerril B (2007) The change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies. Mol Immunol 44:1307–1315. https://doi.org/10.1016/j.molimm.2006.05.009
Quintero-Hernández V, Del Pozo-Yauner L, Pedraza-Escalona M, Juárez-González VR, Alcántara-Recillas I, Possani LD, Becerril B (2012) Evaluation of three different formats of a neutralizing single chain human antibody against toxin Cn2: neutralization capacity versus thermodynamic stability. Immunol Lett 143:152–160. https://doi.org/10.1016/j.imlet.2012.01.010
Ramos OHP, Carmona AK, Selistre-de-Araujo HS (2003) Expression, refolding, and in vitro activation of a recombinant snake venom pro-metalloprotease. Protein Expr Purif 28:34–41. https://doi.org/10.1016/S1046-5928(02)00644-7
Ravi G, Ella K, Lakshmi Narasu M (2008) Development of pilot scale production process and characterization of a recombinant multiepitope malarial vaccine candidate FALVAC-1A expressed in Escherichia coli. Protein Expr Purif 61:57–64. https://doi.org/10.1016/j.pep.2008.05.018
Rezende N., Amaral CF., Freire-Maia L (1998) Immunotherapy for scorpion envenoming in Brazil. Toxicon 36:1507–1513. https://doi.org/10.1016/S0041-0101(98)00141-X
Riaño-Umbarila L, Juárez-González VR, Olamendi-Portugal T, Ortíz-León M, Possani LD, Becerril B (2005) A strategy for the generation of specific human antibodies by directed evolution and phage display. FEBS J 272:2591–2601. https://doi.org/10.1111/j.1742-4658.2005.04687.x
Riaño-Umbarila L, Contreras-Ferrat G, Olamendi-Portugal T, Morelos-Juárez C, Corzo G, Possani LD, Becerril B (2011) Exploiting cross-reactivity to neutralize two different scorpion venoms with one single chain antibody fragment. J Biol Chem 286:6143–6151. https://doi.org/10.1074/jbc.M110.189175
Riaño-Umbarila L, Olamendi-Portugal T, Morelos-Juárez C, Gurrola GB, Possani LD, Becerril B (2013) A novel human recombinant antibody fragment capable of neutralizing Mexican scorpion toxins. Toxicon 76:370–376. https://doi.org/10.1016/j.toxicon.2013.09.016
Riaño-Umbarila L, Ledezma-Candanoza LM, Serrano-Posada H, Fernández-Taboada G, Olamendi-Portugal T, Rojas-Trejo S, Gómez-Ramírez IV, Rudiño-Piñera E, Possani LD, Becerril B (2016) Optimal neutralization of Centruroides noxius venom is understood through a structural complex between two antibody fragments and the Cn2 toxin. J Biol Chem 291:1619–1630. https://doi.org/10.1074/jbc.M115.685297
Riaño-Umbarila L, Rojas-Trejo VM, Romero-Moreno JA, Costas M, Utrera-Espíndola I, Olamendi-Portugal T, Possani LD, Becerril B (2020) Comparative assessment of the VH-VL and VL-VH orientations of single-chain variable fragments of scorpion toxin-neutralizing antibodies. Mol Immunol 122:141–147. https://doi.org/10.1016/j.molimm.2020.04.015
Riaño-Umbarila L, Romero-Moreno JA, Ledezma-Candanoza LM, Olamendi-Portugal T, Possani LD, Becerril B (2021) Full neutralization of centruroides sculpturatus scorpion venom by combining two human antibody fragments. Toxins (basel) 13:1–13. https://doi.org/10.3390/toxins13100708
Roberto PG, Kashima S, Soares AM, Chioato L, Faça VM, Fuly AL, Astolfi-Filho S, Pereira JO, França SC (2004) Cloning and expression of an acidic platelet aggregation inhibitor phospholipase A2 cDNA from Bothrops jararacussu venom gland. Protein Expr Purif 37:102–108. https://doi.org/10.1016/j.pep.2004.05.020
Rodríguez-Rodríguez ER, Ledezma-Candanoza LM, Contreras-Ferrat LG, Olamendi-Portugal T, Possani LD, Becerril B, Riaño-Umbarila L (2012) A single mutation in framework 2 of the heavy variable domain improves the properties of a diabody and a related single-chain antibody. J Mol Biol 423:337–350. https://doi.org/10.1016/j.jmb.2012.07.007
Rodríguez-Rodríguez ER, Olamendi-Portugal T, Serrano-Posada H, Arredondo-López JN, Gómez-Ramírez I, Fernández-Taboada G, Possani LD, Anguiano-Vega GA, Riaño-Umbarila L, Becerril B (2016) Broadening the neutralizing capacity of a family of antibody fragments against different toxins from Mexican scorpions. Toxicon 119:52–63. https://doi.org/10.1016/j.toxicon.2016.05.011
Rosano GL, Ceccarelli EA (2014) Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol 5:1–17. https://doi.org/10.3389/fmicb.2014.00172
Ruiz J, Pinsach J, Álvaro G, González G, de Mas C, Resina D, López-Santín J (2009) Alternative production process strategies in E. coli improving protein quality and downstream yields. Process Biochem 44:1039–1045. https://doi.org/10.1016/j.procbio.2009.05.007
Ruiz J, González G, de Mas C, López-Santín J (2011) A semiempirical model to control the production of a recombinant aldolase in high cell density cultures of Escherichia coli. Biochem Eng J 55:82–91. https://doi.org/10.1016/j.bej.2011.03.001
Salema V, Marín E, Martínez-Arteaga R, Ruano-Gallego D, Fraile S, Margolles Y, Teira X, Gutierrez C, Bodelón G, Fernández LÁ (2013) Selection of single domain antibodies from immune libraries displayed on the surface of E. coli cells with two β-domains of opposite topologies. PLoS ONE 8:1–18. https://doi.org/10.1371/journal.pone.0075126
Schirrmann T, Al-Halabi L, Dübel S, Hust M (2008) Production systems for recombinant antibodies. Front Biosci 13:4576–4594
Schmideder A, Cremer JH, Weuster-Botz D (2016) Parallel steady state studies on a milliliter scale accelerate fed-batch bioprocess design for recombinant protein production with Escherichia coli. Biotechnol Prog 32:1426–1435. https://doi.org/10.1002/btpr.2360
Schofield DJ, Lewis AR, Austin MJ (2014) Genetic methods of antibody generation and their use in immunohistochemistry. Methods 70:20–27. https://doi.org/10.1016/j.ymeth.2014.02.031
Secretaría de Salud de México (2014) Programa de Acción Específico: Prevención y Control de la Intoxicación por Picadura de Alacrán 2013–2018. https://www.gob.mx/salud/documentos/programa-de-accion-especifico-prevencion-y-control-de-la-intoxicacion-por-picadura-de-alacran-2013-2018. Accessed 29 Apr 2023
Selas Castiñeiras T, Williams SG, Hitchcock AG, Smith DC (2018) E. coli strain engineering for the production of advanced biopharmaceutical products. FEMS Microbiol Lett 365:1–10. https://doi.org/10.1093/femsle/fny162
Selisko B, Cosío G, García C, Becerril B, Possani LD, Horjales E (2004) Bacterial expression, purification and functional characterization of a recombinant chimeric Fab derived from murine mAb BCF2 that neutralizes the venom of the scorpion Centruroides noxius hoffmann. Toxicon 43:43–51. https://doi.org/10.1016/j.toxicon.2003.10.015
Shao JH, Wang YQ, Wu XY, Jiang R, Zhang R, Wu CF, Zhang JH (2008) Cloning, expression, and pharmacological activity of BmK AS, an active peptide from scorpion Buthus martensii Karsch. Biotechnol Lett 30:23–29. https://doi.org/10.1007/s10529-007-9499-y
Sieblist C, Jenzsch M, Pohlscheidt M, Lübbert A (2011) Insights into large-scale cell-culture reactors: I. Liquid mixing and oxygen supply. Biotechnol J 6:1532–1546. https://doi.org/10.1002/biot.201000408
Skerra A, Pluckthun A (1988) Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science (80- ) 240:1038–1041. https://doi.org/10.1126/science.3285470
Sofer S, Shahak E, Gueron M (1994) Scorpion envenomation and antivenom therapy. J Pediatr 124:973–978. https://doi.org/10.1016/S0022-3476(05)83196-8
Spadiut O, Capone S, Krainer F, Glieder A, Herwig C (2014) Microbials for the production of monoclonal antibodies and antibody fragments. Trends Biotechnol 32:54–60. https://doi.org/10.1016/j.tibtech.2013.10.002
Steeland S, Vandenbroucke RE, Libert C (2016) Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today 21:1076–1113. https://doi.org/10.1016/j.drudis.2016.04.003
Theakston RD, Warrell D, Griffiths E (2003) Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 41:541–557. https://doi.org/10.1016/S0041-0101(02)00393-8
Tobassum S, Tahir HM, Zahid MT, Gardner QA, Ahsan MM (2018) Effect of milking method, diet, and temperature on venom production in scorpions. J Insect Sci 18:1–7. https://doi.org/10.1093/jisesa/iey081
Toksoy Öner E, Kirdar B, Önsan ZI, Ülgen KÖ (2003) Modeling of the induced expression for high-level production of a foreign protein by recombinant E. coli under the control of the T7 phage promoter. Process Biochem 39:315–323. https://doi.org/10.1016/S0032-9592(03)00077-3
Tokugawa K, Ishii T, Nakamura K, Masaki H, Uozumi T (1994) A model system for the continuous production of a heterologous protein using a novel secretion promoting factor which operates in Escherichia coli. J Biotechnol 37:33–37. https://doi.org/10.1016/0168-1656(94)90199-6
Tripathi NK (2016) Production and purification of recombinant proteins from Escherichia coli. ChemBioEng Rev 3:116–133. https://doi.org/10.1002/cben.201600002
Tscheliessnig AL, Konrath J, Bates R, Jungbauer A (2013) Host cell protein analysis in therapeutic protein bioprocessing - methods and applications. Biotechnol J 8:655–670. https://doi.org/10.1002/biot.201200018
Turkov M, Rashi S, Noam Z, Gordon D, Ben KR, Stankiewicz M, Pelhate M, Gurevitz M (1997) In vitro folding and functional analysis of an anti-insect selective scorpion depressant neurotoxin produced in Escherichia coli. Protein Expr Purif 10:123–131. https://doi.org/10.1006/prep.1997.0724
Valencia-Martínez H, Olamendi-Portugal T, Restano-Cassulini R, Serrano-Posada H, Zamudio F, Possani LD, Riaño-Umbarila L, Becerril B (2022) Characterization of four medically important toxins from Centruroides huichol scorpion venom and its neutralization by a single recombinant antibody fragment. Toxins (basel) 14:369. https://doi.org/10.3390/toxins14060369
Vemula S, Thunuguntla R, Dedaniya A, Kokkiligadda S, Palle C, Ronda SR (2015) Improved production and characterization of recombinant human granulocyte colony stimulating factor from E. coli under optimized downstream processes. Protein Expr Purif 108:62–72. https://doi.org/10.1016/j.pep.2015.01.010
Ward RJ, De Oliveira AHC, Bortoleto RK, Rosa JC, Faça VM, Greene LJ (2001) Refolding and purification of bothropstoxin-I, a Lys49-phospholipase A2homologue, expressed as inclusion bodies in escherichia coli. Protein Expr Purif 21:134–140. https://doi.org/10.1006/prep.2000.1353
Warrell D, Gutierrez J-M, Padilla A (2007) Rabies and envenomings : a neglected public health issue : report of a Consultative Meeting. https://apps.who.int/iris/handle/10665/43858. Accessed 29 Apr 2023
Yang XM (1992) Optimization of a cultivation process for recombinant protein production by Escherichia coli. J Biotechnol 23:271–289. https://doi.org/10.1016/0168-1656(92)90075-K
Yee L, Blanch HW (1992) Recombinant protein expression in high cell density fed-batch cultures of Escherichia coli. Biotechnology (n y) 10:1550–1556
Zheng ZY, Yao SJ, Lin DQ (2005) Using a kinetic model that considers cell segregation to optimize hEGF expression in fed-batch cultures of recombinant Escherichia coli. Bioprocess Biosyst Eng 27:143–152. https://doi.org/10.1007/s00449-004-0376-y
Funding
Susana María Alonso Villela is grateful to the National Council of Science and Technology (CONACYT, Mexico) for the doctoral scholarship No. 461347.
Author information
Authors and Affiliations
Contributions
Conceptualization: SMAV. Investigation: SMAV. Supervision: LF, CAAL. Writing—original draft preparation: SMAV. Writing—editing review: SMAV, HK, BBZ, CB, CAAL, LF.
Corresponding authors
Ethics declarations
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Alonso Villela, S.M., Kraïem-Ghezal, H., Bouhaouala-Zahar, B. et al. Production of recombinant scorpion antivenoms in E. coli: current state and perspectives. Appl Microbiol Biotechnol 107, 4133–4152 (2023). https://doi.org/10.1007/s00253-023-12578-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00253-023-12578-1